NASDAQ
GERN

Geron Corporation

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Geron Corporation Stock Price

Vitals

Today's Low:
$2.25
Today's High:
$2.655
Open Price:
$2.59
52W Low:
$1.95
52W High:
$3.84
Prev. Close:
$2.34
Volume:
18470929

Company Statistics

Market Cap.:
$1.22 billion
Book Value:
0.572
Revenue TTM:
$450000
Operating Margin TTM:
-38653.78%
Gross Profit TTM:
$-93668000
Profit Margin:
0%
Return on Assets TTM:
-33.27%
Return on Equity TTM:
-77.66%

Company Profile

Geron Corporation had its IPO on 1996-06-30 under the ticker symbol GERN.

The company operates in the Healthcare sector and Biotechnology industry. Geron Corporation has a staff strength of 107 employees.

Stock update

Shares of Geron Corporation opened at $2.59 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.25 - $2.66, and closed at $2.3.

This is a -1.71% slip from the previous day's closing price.

A total volume of 18,470,929 shares were traded at the close of the day’s session.

In the last one week, shares of Geron Corporation have slipped by -7.26%.

Geron Corporation's Key Ratios

Geron Corporation has a market cap of $1.22 billion, indicating a price to book ratio of 8.2822 and a price to sales ratio of 571.9769.

In the last 12-months Geron Corporation’s revenue was $450000 with a gross profit of $-93668000 and an EBITDA of $-173563008. The EBITDA ratio measures Geron Corporation's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Geron Corporation’s operating margin was -38653.78% while its return on assets stood at -33.27% with a return of equity of -77.66%.

In Q2, Geron Corporation’s quarterly earnings growth was a positive 0% while revenue growth was a negative 60.3%.

Geron Corporation’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
-2.38

Its diluted EPS in the last 12-months stands at $-0.37 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -2.38. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Geron Corporation’s profitability.

Geron Corporation stock is trading at a EV to sales ratio of 493.5541 and a EV to EBITDA ratio of -6.0818. Its price to sales ratio in the trailing 12-months stood at 571.9769.

Geron Corporation stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$415.30 million
Total Liabilities
$72.57 million
Operating Cash Flow
$0
Capital Expenditure
$202000
Dividend Payout Ratio
0%

Geron Corporation ended 2024 with $415.30 million in total assets and $0 in total liabilities. Its intangible assets were valued at $415.30 million while shareholder equity stood at $298.43 million.

Geron Corporation ended 2024 with $0 in deferred long-term liabilities, $72.57 million in other current liabilities, 522000.00 in common stock, $-1500991000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $56.90 million and cash and short-term investments were $371.38 million. The company’s total short-term debt was $11,628,000 while long-term debt stood at $40.80 million.

Geron Corporation’s total current assets stands at $377.28 million while long-term investments were $28.28 million and short-term investments were $314.48 million. Its net receivables were $1.19 million compared to accounts payable of $7.67 million and inventory worth $535000.00.

In 2024, Geron Corporation's operating cash flow was $0 while its capital expenditure stood at $202000.

Comparatively, Geron Corporation paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$2.3
52-Week High
$3.84
52-Week Low
$1.95
Analyst Target Price
$4.83

Geron Corporation stock is currently trading at $2.3 per share. It touched a 52-week high of $3.84 and a 52-week low of $3.84. Analysts tracking the stock have a 12-month average target price of $4.83.

Its 50-day moving average was $2.85 and 200-day moving average was $2.77 The short ratio stood at 8.58 indicating a short percent outstanding of 0%.

Around 13% of the company’s stock are held by insiders while 6459.6% are held by institutions.

Frequently Asked Questions About Geron Corporation

The stock symbol (also called stock or share ticker) of Geron Corporation is GERN

The IPO of Geron Corporation took place on 1996-06-30

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$38.63
-1.69
-4.19%
$41.77
-1.87
-4.29%
$13.25
-0.09
-0.67%
$28.8
0.05
+0.17%
VIP Clothing Limited (VIPCLOTHNG)
$46.46
-1.23
-2.58%
$74.49
0.02
+0.03%
Afya Ltd (AFYA)
$16.82
-0.04
-0.24%
$40.55
-0.84
-2.03%
$0.42
0.02
+5%
$355.6
-27.5
-7.18%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Address

919 East Hillsdale Boulevard, Foster City, CA, United States, 94404